Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

REGENT PACIFIC GROUP LIMITED
勵晶太平洋集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 575)

Voluntary Operational Update

Update on NDA Status for Fortacin™/Senstend™ in China and Positive Progress at Deep Longevity

This announcement is made on a voluntary basis by the board (the "**Board**") of directors (the "**Director(s)**") of Regent Pacific Group Limited (the "**Company**" and collectively with its subsidiaries, the "**Group**") to inform the shareholders of the Company and potential investors of the following significant update in respect of its operations.

Update on NDA Status for Fortacin™/Senstend™ in China

Further to our announcements of 18 December 2024 and 25 March 2025, the Board is pleased to announce that our commercial strategic partner 江蘇萬邦生化醫藥集團有限責任公司 (Jiangsu Wanbang Biopharmaceutical Group Co., Ltd.) ("**Wanbang Biopharmaceutical**", a wholly-controlled company of 上海復星醫藥（集團）股份有限公司 (Shanghai Fosun Pharmaceutical (Group) Co. Ltd.)) is progressing the new drug application ("**NDA**") for Senstend™ with the National Medical Products Administration ("**NMPA**") in China. In this respect, Wanbang Biopharmaceutial has received the first round of questions from NMPA on the NDA dossier and it has submitted in return a timely and fulsome response.

In support of the NDA application, Wanbang Biopharmaceutical has submitted 900 commercial samples of Senstend™ that were manufactured by its manufacturing partner to the Centre of Drug Evaluation.

Wanbang Biopharmaceutical remains optimistic that NDA approval will be obtained by the end of 2025, with first commercial launch starting in Q1 2026.

Jamie Gibson, CEO of the Group, said, *"We are delighted with the progress that Wanbang Biopharmaceutical is undertaking with the NDA and we look forward to the continued progress of the NDA dossier with NMPA, with approval expected by the end of 2025."*

If the NMPA grants an import licence for Senstend™, US$5 million (or approximately HK$39 million) (before deduction of PRC withholding tax) will be payable to the Group from Wanbang Biopharmaceutical. In addition, upon first commercial sale of Senstend™ in China, US$2 million (or approximately HK$15.60 million) (before deduction of PRC withholding tax) shall be payable to the Group from Wanbang Biopharmaceutical. Also, and as disclosed in the Company's announcement on 25 March 2025, there are other significant payments payable to the Group from Wanbang Biopharmaceutical in respect of commercial milestones and royalties.

About Senstend™

Senstend™ (the brand name for Fortacin™ in China) is a metered dose aerosol from a proprietary formulation of two marketed drugs, lidocaine and prilocaine, developed for treating premature ejaculation ("**PE**"). The disorder affects approximately 20% to 30% of men in China, which translates to a significant initial target male PE population base of approximately 55 million men in China aged between 20-59 years old, based on World Bank population estimates of 2022 rising to over 170 million men. In December 2018, Plethora Solutions Limited, a wholly-owned subsidiary of the Company, signed an exclusive license agreement with Wanbang Biopharmaceutical, to market, distribute and sell Senstend™ for PE in China.

Positive Progress at Deep Longevity

Deep Longevity, Inc, a wholly-owned subsidiary of the Company, ("**Deep Longevity**") is making continued progress with the onboarding of new customers during the first half of this year, with notable new customers being Humansa Health (https://www.humansahealth.com), Hong Kong and Holistica World (https://www.holisticaworld.com), India. Furthermore, usage of the Deep Longevity's aging clocks by customers has increased in the first half of the year as compared to the same period last year, indicating the value of the technology and the increased focus of longevity and wellness as a health trend. Deep Longevity aims to create new partnerships with longevity apps, other platforms, startups and diagnostic companies that have a B2C model.

Deep Longevity is committed to launching aging clocks in the United States ("**US**"), being the largest market for longevity, with the recruitment of a US president to lead the expansion into this market, which is expected to drive the growth of the business. It should be stressed that while the longevity and wellness market is in its infancy, this unique technology is designed to provide entry into this extremely large and growing market estimated to be worth over US$6.3 trillion in 2023.

Deep Longevity has an active pipeline, with the larger discussions ongoing with multiple longevity clinics and other companies interested in using our aging clocks in markets such as Brazil, Germany, and Southeast Asia.

Deep Longevity has also updated its aging clock with Biometric Age that uses 17 blood biomarkers and 4 biometric measures, including blood pressure and waist circumference, providing additional measurements to customers. In addition, Deep Longevity is constantly updating its large language model, which provides more accurate BloodAge and MindAge reports.

Deep Longevity is undertaking further R&D to add a new clock to its product range, called "Face Age" or a "Face Index Score". In addition, Deep Longevity is exploring the addition of other new clocks to its existing product range, focused on the health, beauty and wellness sectors.

About Deep Longevity

Deep Longevity is a wholly-owned subsidiary of the Company, developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine, which enables physicians to make better decisions on the interventions that may slow down or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified herein, the amounts dominated into US$ have been translated, for the purpose of illustration only, into HK$ using the exchange rate of US$1.00 = HK$7.80.

By Order of the Board
Regent Pacific Group Limited
Jamie Gibson
Executive Director

Hong Kong, 22 July 2025

As at the date of this announcement, the Board comprises six Directors**:**

Executive Director:
Jamie Gibson *(Chief Executive Officer)*

Non-Executive Directors:
James Mellon *(Chairman)*
Jayne Sutcliffe

Independent Non-Executive Directors:
Mark Searle
Adrian Chan
Ihsan Al Chalabi